静脉注射免疫球蛋白治疗川崎病所致药物性超敏反应综合征。 - Suppr

Suppr

超能文献

Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease.

作者信息

Satake Mao, Kudo Kyoko, Masuda Akiko, Onoyama Sagano, Furuno Kenji, Furue Masutaka

机构信息

Departments of, Department of, Dermatology, Fukuoka Children's Hospital, Fukuoka, Japan.

Department of, General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.

出版信息

J Dermatol. 2020 Mar;47(3):e74-e75. doi: 10.1111/1346-8138.15211. Epub 2020 Jan 5.

DOI:10.1111/1346-8138.15211

PMID:31903619

Abstract

摘要

相似文献

Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease.

J Dermatol. 2020 Mar;47(3):e74-e75. doi: 10.1111/1346-8138.15211. Epub 2020 Jan 5.

Marked pleural effusion after i.v. immunoglobulin therapy for Kawasaki disease.

Pediatr Int. 2018 Mar;60(3):307-308. doi: 10.1111/ped.13489. Epub 2018 Feb 26.

Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.

Am J Hematol. 2000 Mar;63(3):160-1. doi: 10.1002/(sici)1096-8652(200003)63:3<160::aid-ajh11>3.0.co;2-4.

Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease.

BMJ Case Rep. 2019 Mar 21;12(3):e229596. doi: 10.1136/bcr-2019-229596.

[Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease].

An Pediatr (Barc). 2011 Jul;75(1):79-80. doi: 10.1016/j.anpedi.2010.11.019. Epub 2011 Mar 21.

Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.

J Pediatr. 2006 Mar;148(3):399-400. doi: 10.1016/j.jpeds.2005.10.027.

Role of intravenous immunoglobulin in the treatment of Kawasaki disease.

Int J Rheum Dis. 2018 Jan;21(1):64-69. doi: 10.1111/1756-185X.13220. Epub 2017 Dec 5.

Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.

Pediatr Allergy Immunol. 2008 Mar;19(2):184-5. doi: 10.1111/j.1399-3038.2007.00657.x.

[High-dose intravenous immunoglobulin treatment].

Nihon Rinsho. 2008 Feb;66(2):327-31.

Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.

Pediatr Allergy Immunol. 2008 Mar;19(2):186-7. doi: 10.1111/j.1399-3038.2007.00658.x.

引用本文的文献

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.

Am J Clin Dermatol. 2024 Jul;25(4):609-621. doi: 10.1007/s40257-024-00867-y. Epub 2024 May 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease.

作者信息

Satake Mao, Kudo Kyoko, Masuda Akiko, Onoyama Sagano, Furuno Kenji, Furue Masutaka

机构信息

Departments of, Department of, Dermatology, Fukuoka Children's Hospital, Fukuoka, Japan.

Department of, General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.

出版信息

J Dermatol. 2020 Mar;47(3):e74-e75. doi: 10.1111/1346-8138.15211. Epub 2020 Jan 5.

DOI:10.1111/1346-8138.15211

PMID:31903619

Abstract

摘要

相似文献

Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease.

J Dermatol. 2020 Mar;47(3):e74-e75. doi: 10.1111/1346-8138.15211. Epub 2020 Jan 5.

Marked pleural effusion after i.v. immunoglobulin therapy for Kawasaki disease.

Pediatr Int. 2018 Mar;60(3):307-308. doi: 10.1111/ped.13489. Epub 2018 Feb 26.

Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.

Am J Hematol. 2000 Mar;63(3):160-1. doi: 10.1002/(sici)1096-8652(200003)63:3<160::aid-ajh11>3.0.co;2-4.

Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease.

BMJ Case Rep. 2019 Mar 21;12(3):e229596. doi: 10.1136/bcr-2019-229596.

[Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease].

An Pediatr (Barc). 2011 Jul;75(1):79-80. doi: 10.1016/j.anpedi.2010.11.019. Epub 2011 Mar 21.

Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.

J Pediatr. 2006 Mar;148(3):399-400. doi: 10.1016/j.jpeds.2005.10.027.

Role of intravenous immunoglobulin in the treatment of Kawasaki disease.

Int J Rheum Dis. 2018 Jan;21(1):64-69. doi: 10.1111/1756-185X.13220. Epub 2017 Dec 5.

Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.

Pediatr Allergy Immunol. 2008 Mar;19(2):184-5. doi: 10.1111/j.1399-3038.2007.00657.x.

[High-dose intravenous immunoglobulin treatment].

Nihon Rinsho. 2008 Feb;66(2):327-31.

Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.

Pediatr Allergy Immunol. 2008 Mar;19(2):186-7. doi: 10.1111/j.1399-3038.2007.00658.x.

引用本文的文献

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.

Am J Clin Dermatol. 2024 Jul;25(4):609-621. doi: 10.1007/s40257-024-00867-y. Epub 2024 May 16.